Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance
- PMID: 20047818
- DOI: 10.1016/j.ijantimicag.2009.10.024
Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance
Abstract
Infection due to Acinetobacter baumannii has become a significant challenge to modern healthcare systems. The organism shows a formidable capacity to develop antimicrobial resistance, yet the clinical impact of A. baumannii infection remains unclear. Much is known about the processes involved in multidrug resistance, but those underlying the pathogenicity and virulence potential of the organism are only beginning to be elucidated. In this article, we provide an overview of current knowledge, focusing on mechanisms of pathogenesis, the molecular basis of resistance and options for treatment in the absence of novel therapeutic agents.
Copyright 2009 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
Similar articles
-
Acinetobacter baumannii: an emerging multidrug-resistant threat.Expert Rev Anti Infect Ther. 2008 Jun;6(3):309-25. doi: 10.1586/14787210.6.3.309. Expert Rev Anti Infect Ther. 2008. PMID: 18588496 Review.
-
Therapeutic options for Acinetobacter baumannii infections.Expert Opin Pharmacother. 2008 Mar;9(4):587-99. doi: 10.1517/14656566.9.4.587. Expert Opin Pharmacother. 2008. PMID: 18312160 Review.
-
Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy.Expert Rev Anti Infect Ther. 2010 Jan;8(1):71-93. doi: 10.1586/eri.09.108. Expert Rev Anti Infect Ther. 2010. PMID: 20014903 Review.
-
Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options.Clin Infect Dis. 2008 Apr 15;46(8):1254-63. doi: 10.1086/529198. Clin Infect Dis. 2008. PMID: 18444865 Review.
-
Treating multidrug-resistant Acinetobacter baumannii infection by blocking its virulence factors.Expert Rev Anti Infect Ther. 2013 Mar;11(3):231-3. doi: 10.1586/eri.13.11. Expert Rev Anti Infect Ther. 2013. PMID: 23458763 Review. No abstract available.
Cited by
-
Non-nucleoside inhibitors of BasE, an adenylating enzyme in the siderophore biosynthetic pathway of the opportunistic pathogen Acinetobacter baumannii.J Med Chem. 2013 Mar 28;56(6):2385-405. doi: 10.1021/jm301709s. Epub 2013 Mar 13. J Med Chem. 2013. PMID: 23437866 Free PMC article.
-
Impact of target site mutations and plasmid associated resistance genes acquisition on resistance of Acinetobacter baumannii to fluoroquinolones.Sci Rep. 2021 Oct 11;11(1):20136. doi: 10.1038/s41598-021-99230-y. Sci Rep. 2021. PMID: 34635692 Free PMC article.
-
Semi-Synthetic Glycoconjugate Vaccine Lead Against Acinetobacter baumannii 17978.Angew Chem Int Ed Engl. 2022 Oct 10;61(41):e202209556. doi: 10.1002/anie.202209556. Epub 2022 Sep 1. Angew Chem Int Ed Engl. 2022. PMID: 35950629 Free PMC article.
-
Co-occurrence of carbapenem and aminoglycoside resistance genes among multidrug-resistant clinical isolates of Acinetobacter baumannii from Cracow, Poland.Med Sci Monit Basic Res. 2014 Jan 27;20:9-14. doi: 10.12659/MSMBR.889811. Med Sci Monit Basic Res. 2014. PMID: 24463791 Free PMC article.
-
In vitro activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii carrying various β-lactamase encoding genes.Eur J Clin Microbiol Infect Dis. 2024 Jun;43(6):1171-1179. doi: 10.1007/s10096-024-04831-w. Epub 2024 Apr 23. Eur J Clin Microbiol Infect Dis. 2024. PMID: 38652417 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources